The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI.

Am Heart JJun 16, 2026 (epub)
Clinical ResearchCardiology

James L Januzzi, C Michael Gibson, Gerald Chi et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of zalunfiban on high sensitivity cardiac troponin T (hs-cTnT) levels and clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). The study found that zalunfiban treatment resulted in lower hs-cTnT levels at 24 hours compared to placebo, indicating reduced myocardial infarction size and improved clinical outcomes.

Key findings

  • Higher hs-cTnT at presentation was linked to less ST deviation resolution (P = .006).
  • Elevated hs-cTnT at 24 hours increased the risk of all-cause death (OR 1.83 per log unit increase; P = .03).
  • Zalunfiban treatment led to lower hs-cTnT levels compared to placebo at 24 hours (P = .04).
  • Zalunfiban resulted in smaller hs-cTnT determined myocardial infarction size.

Why it matters

Understanding the relationship between hs-cTnT levels and clinical outcomes can help clinicians assess the severity of myocardial infarction and the effectiveness of treatments like zalunfiban in improving patient prognosis.

Source

PubMed · PMID 42303064

Published in Am Heart J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.